Clinical Presentation of <i>MTAP</i> Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies
<i>MTAP</i> is a key biomarker in precision oncology; this work describes the clinical outlook for these patients within the community-oncology setting. These insights can inform future study design, as <i>MTAP</i>-directed therapies continue their development.
Authors
- Daniel J. Luckett (ORCID: https://orcid.org/0000-0002-6358-9081)
- David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
- D. Schlauch
- Xiaotong Fu
- Emma Sturgill (ORCID: https://orcid.org/0000-0003-2855-5297)
- Vivek Subbiah (ORCID: https://orcid.org/0000-0002-6064-6837)
- Andrew J. McKenzie (ORCID: https://orcid.org/0000-0002-5088-1876)
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Jordan T. Best (ORCID: https://orcid.org/0000-0003-2827-7143)
- Howard A. Burris (ORCID: https://orcid.org/0000-0002-1501-2931)
- Alison Bradley
- Sripraharsha S Jampana Raju (ORCID: https://orcid.org/0009-0002-8902-7164)
Institutions
- Medpace (United States) (US)
- Centennial Medical Center (US)
- Sarah Cannon (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1200/po-25-00564
- Citations
- 1
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81